Saturday, June 22, 2024

Brain Chip: Neuralink Gains FDA Approval for Second Implantation Despite Initial Complications

Similar articles

Neuralink, the brain-computer interface company founded by Elon Musk, has received the Food and Drug Administration (FDA) approval to proceed with implanting its brain chip in a second patient, just a week after disclosing complications with its first patient. The initial patient, Noland Arbaugh, who was paralyzed from the shoulders down following a diving accident in 2016, experienced issues with some of the brain chip’s electrode-studded threads retracting out of position, resulting in a reduction in the number of effective electrodes that could measure brain signals.

Despite these challenges, Neuralink has been given the green light by the FDA to proceed with implanting the brain chip in a second individual after proposing a fix to address the complications observed in the first patient. The brain chip, roughly the size of a coin, is implanted in the brain and consists of 64 tiny threads equipped with over 1,000 electrodes to read neuron activity. This neural activity can then be decoded to control computers, smartphones, and tablets using only the power of thought.

The first brain chip implantation surgery on Noland Arbaugh was deemed successful, allowing him to control various devices, including a laptop, through the neural interface. However, complications arose when some of the threads began retracting from the brain, resulting in decreased functionality of the device. Neuralink has since adjusted its algorithm to restore the implant’s ability to monitor brain signals effectively.

Neuralink Advances Brain Chip Trials Despite Risks, Plans Broader Implantations in 2024

Despite being aware of the potential for these complications, both Neuralink and the FDA deemed the risk sufficiently low to proceed with the in-human trials. Looking ahead, Neuralink plans to embed some of the brain chip’s wires deeper into the brain tissue to mitigate the risk of thread retraction in future patients. However, this approach may introduce additional challenges, including the potential for brain tissue damage if the threads dislodge or if the device needs to be removed.

Neuralink’s ambitious timeline includes the implantation of the brain-computer interface device in the second patient by June, marking a crucial step forward in the company’s mission to revolutionize neural technology. Beyond this initial milestone, Neuralink plans to expand its reach by implanting the device in a total of 10 individuals throughout 2024. This concerted effort reflects Neuralink’s commitment to advancing the field of brain-computer interfaces and exploring the full spectrum of possibilities for enhancing human capabilities through neural technology.

The overwhelming response from the quadriplegic community underscores the profound impact that brain-computer interface technology could have on the lives of individuals with mobility impairments. With over 1,000 quadriplegics already enrolled in Neuralink’s patient registry, there is clear enthusiasm and anticipation surrounding the potential benefits of this groundbreaking technology. These individuals are eager to participate in clinical trials and contribute to the ongoing development of Neuralink’s neural interface technology, recognizing its potential to restore independence and improve quality of life.

Brain Chip

Neuralink Prioritizes Safety and Innovation in Brain-Computer Interface Development

As Neuralink continues to refine its implantation procedures and optimize the functionality of its brain-computer interface device, the company remains committed to prioritizing patient safety and efficacy. Each implantation represents a unique opportunity to gather valuable data and insights, informing future advancements and ensuring that Neuralink’s technology meets the highest standards of performance and reliability.

Furthermore, Neuralink’s collaborative approach to research and development fosters partnerships with leading medical institutions and researchers, facilitating the exchange of knowledge and expertise in the field of neural engineering. By harnessing the collective wisdom of multidisciplinary teams, Neuralink is well-positioned to tackle the complex challenges inherent in developing neural interface technology and unlock new possibilities for human-machine interaction.

You can follow our news on our Telegram and LinkedIn accounts.

Looking ahead, Neuralink’s ambitious goals extend beyond mere implantation numbers. The company envisions a future where brain-computer interfaces seamlessly integrate into everyday life, empowering individuals to interact with technology in novel ways and overcome physical limitations. Through continued innovation and collaboration, Neuralink is poised to redefine what’s possible in the realm of neural technology, paving the way for a more connected and inclusive future for all. In addition to improving cursor control performance, Neuralink intends to expand the functionality of its implant to enable control of robotic arms, wheelchairs, and other assistive technologies, offering greater independence to individuals living with quadriplegia.


Resource: Medical Device and Diagnostic Industry, May 20, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article